gland pharma glp-1 capacity FY25 Results: Strong Margins, 31 Product Launches | Harshal Jain posted on the topic Gland Pharma net profit rises

And those studies I think what when I look at MCAS and when I look at autoimmune N of one, like maybe N of ten, like I, you know, I think these smaller studies I think provide so much more value because for so many of us, our patients dont align in a large RCT like it just isnt, you know, within there

[DOI] [PubMed] [Google Scholar] 319.Anini Y., Hansotia T., Brubaker P.L

Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial

Across multiple trials and medicines

The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisks Wegovy, and on attempts to bypass the regulatory approval process through compounded formulations

muciniphila had no effect